Pharmacoepidemiological research with large health databases

被引:20
作者
Andersohn, F. [1 ,2 ]
Garbe, E. [1 ,2 ]
机构
[1] Univ Bremen, D-2800 Bremen 33, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
关键词
Secondary data; pharmacoepidemiology; databases; drug safety; Germany;
D O I
10.1007/s00103-008-0648-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Over the years there has been an increase in the number of pharmacoepidemiological studies using secondary data from large health databases. Administrative health databases consist of data recorded within the health care system for reasons of billing. Physician-based databases use data derived from electronic medical records. In both types of databases, data are recorded prospectively and may include demographic information, lifestyle information, ambulatory consultations, drug prescriptions, ambulatory and in-hospital diagnoses, ambulatory services, laboratory values, hospitalizations and information on death. Health databases are valuable for research on drug utilization and drug effects, but they are also increasingly used for disease epidemiology studies. In recent years, most new drugs within the European Union have been approved with the requirement of active post-marketing surveillance for investigation of drug utilization or monitoring of drug safety. This implies an increasing need for valid data sources. Large health databases are important instruments for the detection of unknown drug risks and for the investigation of new safety signals derived from spontaneous reporting systems.
引用
收藏
页码:1135 / 1144
页数:10
相关论文
共 48 条
[1]   Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study [J].
Ahrens, Wolfgang ;
Hagemeier, Constantin ;
Muehlbauer, Bernd ;
Pigeot, Iris ;
Puentmann, Isabel ;
Reineke, Achim ;
Steinbach, Monica ;
Timm, Juergen .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (12) :1298-1307
[2]   Use of first- and second-generation cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction [J].
Andersohn, F ;
Suissa, S ;
Garbe, E .
CIRCULATION, 2006, 113 (16) :1950-1957
[3]   Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke - A nested case-control study [J].
Andersohn, Frank ;
Schade, Rene ;
Suissa, Samy ;
Garbe, Edeltraut .
STROKE, 2006, 37 (07) :1725-1730
[4]  
BLACKBURN S, 2008, PERS MITT RAHM EUR N
[5]  
Carlson A M, 1996, J Am Pharm Assoc (Wash), VNS36, P263
[6]  
De Bruin ML, 2002, ANN PHARMACOTHER, V36, P338
[7]   Doctors' prescription behaviour regarding dosage recommendations for preparations of kava extracts [J].
Dietlein, G ;
Schröder-Bernhardi, D .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (05) :417-421
[8]   Study subjects and ordinary patients [J].
Dowd, R ;
Recker, RR ;
Heaney, RP .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (06) :533-536
[9]  
*EUR MED AG, EMEAH3416303 EUR MED
[10]  
*EUR MED AG COMM M, EMEACHMP962682005 EU